96 related articles for article (PubMed ID: 7495122)
1. Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy.
Cespedes RD; Peretsman SJ; Thompson IM; Jackson C
Urology; 1995 Nov; 46(5):688-91. PubMed ID: 7495122
[TBL] [Abstract][Full Text] [Related]
2. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
[TBL] [Abstract][Full Text] [Related]
3. Protection against procarbazine-induced testicular damage by GnRH-agonist and antiandrogen treatment in the rat.
Kangasniemi M; Wilson G; Huhtaniemi I; Meistrich ML
Endocrinology; 1995 Aug; 136(8):3677-80. PubMed ID: 7628410
[TBL] [Abstract][Full Text] [Related]
4. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H; Senge T
J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
6. Prolonged suppression of spermatogenesis by oestrogen does not preserve the seminiferous epithelium in procarbazine-treated rats.
Morris ID; Bardin CW; Gunsalus G; Ward JA
Int J Androl; 1990 Jun; 13(3):180-9. PubMed ID: 2117584
[TBL] [Abstract][Full Text] [Related]
7. The effects of GnRH analogues and antiandrogenes in preventing the gonadotoxic effects of COPP chemotherapy.
Göçmen M; Akay AF; Sahin H; Deniz M; Nergiz Y; Bircan MK
Int Urol Nephrol; 2001; 33(4):651-4. PubMed ID: 12452621
[TBL] [Abstract][Full Text] [Related]
8. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
Goldspiel BR; Kohler DR
DICP; 1991; 25(7-8):796-804. PubMed ID: 1835221
[TBL] [Abstract][Full Text] [Related]
9. Rapid protection of rat spermatogenic stem cells against procarbazine by treatment with a gonadotropin-releasing hormone antagonist (Nal-Glu) and an antiandrogen (flutamide).
Kangasniemi M; Wilson G; Parchuri N; Huhtaniemi I; Meistrich ML
Endocrinology; 1995 Jul; 136(7):2881-8. PubMed ID: 7789313
[TBL] [Abstract][Full Text] [Related]
10. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
J Urol; 1991 Nov; 146(5):1321-6. PubMed ID: 1834864
[TBL] [Abstract][Full Text] [Related]
11. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
12. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
[TBL] [Abstract][Full Text] [Related]
13. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
Denis LJ; Carnelro de Moura JL; Bono A; Sylvester R; Whelan P; Newling D; Depauw M
Urology; 1993 Aug; 42(2):119-29; discussion 129-30. PubMed ID: 8367920
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
[TBL] [Abstract][Full Text] [Related]
15. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
17. Connexin 43 expression in Sprague-Dawley rat seminiferous epithelium after in utero exposure to flutamide.
Cai C; Zhao D; Ma C; Zhang Y; Wu X; Wei G; He D
Syst Biol Reprod Med; 2014 Oct; 60(5):257-62. PubMed ID: 24865629
[TBL] [Abstract][Full Text] [Related]
18. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats.
Karashima T; Zalatnai A; Schally AV
Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2329-33. PubMed ID: 2965391
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
